A B Gottlieb

Summary

Affiliation: New Jersey
Country: USA

Publications

  1. ncbi request reprint A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis
    Gerald G Krueger
    Department of Dermatology, University of Utah School of Medicine, Salt Lake City, UT 84132 2409, USA
    J Dermatolog Treat 19:146-55. 2008
  2. ncbi request reprint A randomized trial of etanercept as monotherapy for psoriasis
    Alice B Gottlieb
    Clinical Research Center, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, 08901 0019, USA
    Arch Dermatol 139:1627-32; discussion 1632. 2003
  3. ncbi request reprint Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial
    A B Gottlieb
    UMDNJ Robert Wood Johnson Medica School, New Brunswick, NJ, USA
    Br J Dermatol 152:1219-27. 2005
  4. ncbi request reprint Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study
    A B Gottlieb
    Clinical Research Center, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA
    J Am Acad Dermatol 43:595-604. 2000
  5. ncbi request reprint CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study
    Alice B Gottlieb
    Clinical Research Center, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick 08901 0019, USA
    J Am Acad Dermatol 49:816-25. 2003
  6. ncbi request reprint A case of familial psoriasis with predominant hand involvement
    Alice B Gottlieb
    UMDNJ Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903, USA
    J Cutan Med Surg 7:464-6. 2003
  7. ncbi request reprint Novel immunotherapies for psoriasis: clinical research delivers new hope for patients and scientific advances
    Alice B Gottlieb
    Clinical Research Center, UMDNJ Robert Wood Johnson Medical School, New Brunswick, New Jersey 08901 0019, USA
    J Investig Dermatol Symp Proc 9:79-83. 2004
  8. ncbi request reprint Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis
    Alice B Gottlieb
    Clinical Research Center, UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ 08901 0019, USA
    Clin Immunol 111:28-37. 2004
  9. ncbi request reprint Safety and efficacy of alefacept in elderly patients and other special populations
    Alice B Gottlieb
    UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ 08901 0019, USA
    J Drugs Dermatol 4:718-24. 2005
  10. ncbi request reprint Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial
    Alice B Gottlieb
    University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
    J Am Acad Dermatol 51:534-42. 2004

Detail Information

Publications70

  1. ncbi request reprint A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis
    Gerald G Krueger
    Department of Dermatology, University of Utah School of Medicine, Salt Lake City, UT 84132 2409, USA
    J Dermatolog Treat 19:146-55. 2008
    ..To evaluate the safety and efficacy of multiple courses of alefacept in combination with traditional psoriasis therapy for the treatment of chronic plaque psoriasis (CPP)...
  2. ncbi request reprint A randomized trial of etanercept as monotherapy for psoriasis
    Alice B Gottlieb
    Clinical Research Center, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, 08901 0019, USA
    Arch Dermatol 139:1627-32; discussion 1632. 2003
    ..To determine safety and efficacy of monotherapy with etanercept...
  3. ncbi request reprint Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial
    A B Gottlieb
    UMDNJ Robert Wood Johnson Medica School, New Brunswick, NJ, USA
    Br J Dermatol 152:1219-27. 2005
    ..There is a need for safe and effective alternative treatments for patients with moderate to severe psoriasis...
  4. ncbi request reprint Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study
    A B Gottlieb
    Clinical Research Center, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA
    J Am Acad Dermatol 43:595-604. 2000
    ..Psoriasis is a chronic disease for which treatment with multiple doses of monoclonal antibodies is likely to be required for adequate control...
  5. ncbi request reprint CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study
    Alice B Gottlieb
    Clinical Research Center, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick 08901 0019, USA
    J Am Acad Dermatol 49:816-25. 2003
    ..Alefacept, human LFA-3/IgG(1) fusion protein, selectively reduces memory-effector (CD45RO(+)) T cells, a source of the pathogenic mediators of psoriasis...
  6. ncbi request reprint A case of familial psoriasis with predominant hand involvement
    Alice B Gottlieb
    UMDNJ Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903, USA
    J Cutan Med Surg 7:464-6. 2003
    ..All patients developed psoriasis at 5 years of age. Only one member of this family has involvement in an area other than the hands. This case illustrates some of the complexities of the genetics of psoriasis...
  7. ncbi request reprint Novel immunotherapies for psoriasis: clinical research delivers new hope for patients and scientific advances
    Alice B Gottlieb
    Clinical Research Center, UMDNJ Robert Wood Johnson Medical School, New Brunswick, New Jersey 08901 0019, USA
    J Investig Dermatol Symp Proc 9:79-83. 2004
    ..This approach has wide applicability to other immune-mediated inflammatory isorders...
  8. ncbi request reprint Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis
    Alice B Gottlieb
    Clinical Research Center, UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ 08901 0019, USA
    Clin Immunol 111:28-37. 2004
    ..Reduction in lesional, activated T cells induces improvement in psoriatic plaques. Galiximab (IDEC-114), an IgG(1) anti-CD80 antibody, binds to CD80, a costimulatory molecule involved in T-cell activation...
  9. ncbi request reprint Safety and efficacy of alefacept in elderly patients and other special populations
    Alice B Gottlieb
    UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ 08901 0019, USA
    J Drugs Dermatol 4:718-24. 2005
    ..We assessed the safety and efficacy of alefacept in elderly, obese, and diabetic patients with moderate to severe chronic plaque psoriasis by integrating data from phase 2 and 3 clinical studies and their extensions...
  10. ncbi request reprint Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial
    Alice B Gottlieb
    University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
    J Am Acad Dermatol 51:534-42. 2004
    ..Tumor necrosis factor-alpha is a key mediator in the pathogenesis of psoriasis. Infliximab is a monoclonal antibody that specifically binds to tumor necrosis factor-alpha, blocking its biologic activity...
  11. ncbi request reprint Alefacept is well tolerated in patients with chronic plaque psoriasis
    Alice B Gottlieb
    Clinical Research Center, UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
    J Cutan Med Surg 8:14-9. 2004
    ..Alefacept offers hope for a safer means to provide long-term management of psoriasis...
  12. ncbi request reprint Therapeutic options in the treatment of psoriasis and atopic dermatitis
    Alice B Gottlieb
    Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ 08901, USA
    J Am Acad Dermatol 53:S3-16. 2005
    ..In many of these categories, a number of exciting new therapies are in development that may augment the existing armamentarium available to clinicians for the treatment of inflammatory skin diseases...
  13. ncbi request reprint The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison
    Alice B Gottlieb
    Clinical Research Center, UMDNJ Robert Wood Johnson Medical School, 51 French Street, New Brunswick, NJ 08901 0019, USA
    J Drugs Dermatol 2:260-6. 2003
    ..Our results indicated that NPF-PS was strongly correlated with PASI and PGA in this study, while better reflecting patient perception. This is the first report of a double-blind placebo-controlled study demonstrating this concordance...
  14. ncbi request reprint Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis
    Alice B Gottlieb
    Clinical Research Center, University of Medicine and Dentistry of New Jersey The Robert Wood Johnson Medical School, New Brunswick, NJ 08901 0019, USA
    J Am Acad Dermatol 48:829-35. 2003
    ..Effective, rapid-acting, safe therapies are needed for the long-term treatment of psoriasis...
  15. ncbi request reprint Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris
    Alice B Gottlieb
    Clinical Research Center, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, New Jersey 08901 0019, USA
    J Am Acad Dermatol 48:68-75. 2003
    ..Herein we describe the pharmacodynamic and pharmacokinetic results observed in this clinical trial...
  16. ncbi request reprint Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody
    Alice B Gottlieb
    University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, Clinical Research Center, New Brunswick, NJ 08903 0019, USA
    Arch Dermatol 138:591-600. 2002
    ..Leukocyte function-associated antigen 1 (LFA-1), consisting of CD11a and CD18 subunits, plays an important role in T-cell activation and leukocyte extravasation...
  17. ncbi request reprint The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions
    Alice B Gottlieb
    Clinical Research Center, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, New Jersey 08901 0019, USA
    J Cutan Med Surg 7:185-92. 2003
    ....
  18. ncbi request reprint Clinical research helps elucidate the role of tumor necrosis factor-alpha in the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes
    A B Gottlieb
    Clinical Research Center, UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ 08901 0019, USA
    Lupus 12:190-4. 2003
    ....
  19. ncbi request reprint Psoriasis. Immunopathology and immunomodulation
    A B Gottlieb
    Clinical Research Center, University of Medicine and Dentistry New Jersey Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
    Dermatol Clin 19:649-57, viii. 2001
    ..Immunomodulators used as therapeutic, pathogenic probes will continue to identify targets that play primary roles in the pathogenesis of psoriasis...
  20. ncbi request reprint Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis
    Alice B Gottlieb
    Clinical Research Center, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903 0019, USA
    J Cutan Med Surg 7:198-207. 2003
    ..Phase I and Phase II studies in patients with moderate to severe plaque psoriasis demonstrated that intravenous (IV) efalizumab improved clinical signs and symptoms and was well tolerated...
  21. ncbi request reprint Recombinantly engineered human proteins: transforming the treatment of psoriasis
    Alice B Gottlieb
    Clinical Research Center, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick 08901, USA
    Clin Immunol 105:105-16. 2002
    ..In this article, the mechanisms of T cell pathogenicity that guided the development of these new biologic therapies are reviewed along with clinical data on the progress of these agents...
  22. ncbi request reprint Mechanisms of action of etanercept in psoriasis
    Jennifer K Tan
    Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, USA
    J Investig Dermatol Symp Proc 12:38-45. 2007
    ..The anti-inflammatory properties of etanercept reveal mechanisms by which a TNF blockade may result in the improvement of psoriasis...
  23. ncbi request reprint A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis
    Alan Menter
    Division of Dermatology, Baylor University Medical Center, UT Southwestern Medical School, 5310 Harvest Hill Rd, Ste 260, Dallas, TX 75230, USA
    J Am Acad Dermatol 56:31.e1-15. 2007
    ..Previous studies of infliximab in psoriasis have demonstrated rapid improvement with induction therapy and sustained response with regularly administered maintenance therapy...
  24. ncbi request reprint Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis
    Stephen Tyring
    Department of Dermatology, The University of Texas Health Center at Houston, 6655 Travis, Suite 120, Houston, TX 77030, and Evanston Northwest Healthcare, Skokie, IL, USA
    Arch Dermatol 143:719-26. 2007
    ..To evaluate the safety and efficacy of long-term treatment of psoriasis with etanercept, 50 mg twice weekly...
  25. ncbi request reprint Psoriatic arthritis: a guide for dermatology nurses
    Alice B Gottlieb
    University of Medicine and Dentistry of New Jersey UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ, USA
    Dermatol Nurs 15:107-10, 113-8; quiz 119. 2003
    ..It is imperative that dermatology nurses learn more about the basic immunology of psoriasis and PsA and the role of immunomodulation in their treatments...
  26. ncbi request reprint Etanercept as monotherapy in patients with psoriasis
    Craig L Leonardi
    Saint Louis University School of Medicine, St Louis, USA
    N Engl J Med 349:2014-22. 2003
    ..Inflammatory cytokines such as tumor necrosis factor (TNF) have been implicated in the pathogenesis of psoriasis. We evaluated the safety and efficacy of etanercept, a TNF antagonist, for the treatment of plaque psoriasis...
  27. ncbi request reprint Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. part II
    Kim A Papp
    University of Western Ontario, Waterloo, Ont, Canada
    J Cutan Med Surg 9:313-23. 2005
    ..The efficacy and safety of efalizumab have been evaluated in multiple clinical trials...
  28. ncbi request reprint Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
    U Chaudhari
    Clinical Research Center, UMDNJ-Robert Wood Johnson Medical School, 51 French Street, New Brunswick, NJ 08901-0019, USA
    Lancet 357:1842-7. 2001
    ..These findings suggest that TNF-alpha has a pivotal role in the pathogenesis of psoriasis...
  29. ncbi request reprint Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study
    Carin Gribetz
    Mt Sinai School of Medicine, Department of Dermatology, New York, New York, USA
    J Am Acad Dermatol 51:731-8. 2004
    ..Pimecrolimus, a well-tolerated, nonatrophogenic, skin-selective inflammatory cytokine inhibitor, has been shown to be effective in the treatment of psoriasis when applied topically under occlusion...
  30. doi request reprint Psoriasis comorbidities
    Alice B Gottlieb
    Tufts New England Medical Center, Boston, MA 02111 1533, USA
    J Dermatolog Treat 19:5-21. 2008
    ..Recent studies investigating the effects of tumor necrosis factor antagonists on the treatment of cardiovascular disease and metabolic syndrome support this concept...
  31. ncbi request reprint Relapse, rebound, and psoriasis adverse events: an advisory group report
    Wayne Carey
    Royal Victoria Hospital, Montreal, Quebec, Canada
    J Am Acad Dermatol 54:S171-81. 2006
    ....
  32. ncbi request reprint Biologic therapies for psoriasis. A systematic review
    Wolf Henning Boehncke
    Department of Dermatology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    J Rheumatol 33:1447-51. 2006
    ..In this evidence-based review of the literature, we assess the effects on psoriasis of induction therapy with 5 biologics and provide preliminary treatment guidelines...
  33. doi request reprint Etanercept treatment for children and adolescents with plaque psoriasis
    Amy S Paller
    Children s Memorial Hospital and Department of Dermatology, Northwestern University Medical School, Chicago, IL 60611 2941, USA
    N Engl J Med 358:241-51. 2008
    ..We assessed the efficacy and safety of etanercept in children and adolescents with moderate-to-severe plaque psoriasis...
  34. pmc Alefacept for psoriasis and psoriatic arthritis
    A B Gottlieb
    Clinical Research Center, UMDNJ Robert Wood Johnson Medical School, 51 French St, New Brunswick, NJ 08901 0019, USA
    Ann Rheum Dis 64:iv58-60. 2005
    ..It is marketed in many countries for the treatment of moderate to severe psoriasis. This paper reviews the data supporting the use of alefacept in psoriasis and psoriatic arthritis...
  35. ncbi request reprint Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients
    Rama Malaviya
    Division of Clinical Pharmacology, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick 08903 0019, USA
    J Am Acad Dermatol 55:590-7. 2006
    ..We hypothesized that etanercept decreases inflammatory cell infiltration by inducing apoptosis...
  36. ncbi request reprint Biologic treatments for psoriasis
    Cindy D Kipnis
    University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, New Jersey 08901 0019, USA
    J Am Acad Dermatol 52:671-82. 2005
  37. ncbi request reprint Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy
    Kenneth B Gordon
    Loyola University, Maywood, IL, USA
    J Dermatolog Treat 17:9-17. 2006
    ....
  38. ncbi request reprint Ability to develop rhus allergic contact dermatitis in a patient with psoriasis receiving etanercept
    Wendy Myers
    J Am Acad Dermatol 55:S127-8. 2006
  39. ncbi request reprint Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial
    Craig L Leonardi
    Saint Louis University School of Medicine, St Louis, Missouri, USA
    J Am Acad Dermatol 52:425-33. 2005
    ..Efalizumab inhibits multiple T-cell-mediated processes...
  40. ncbi request reprint Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis
    Michael Jarratt
    DermResearch, Inc Austin, TX, USA
    J Drugs Dermatol 3:367-73. 2004
    ..The novel short contact shampoo formulation of clobetasol propionate is convenient and efficacious and minimizes systemic exposure while being efficient, safe and well-tolerated in the treatment of moderate to severe scalp psoriasis...
  41. ncbi request reprint A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis
    Alice B Gottlieb
    Department of Dermatology, Tufts New England Medical Center, Boston, MA 02111, USA
    Curr Med Res Opin 23:1081-92. 2007
    ..c.) administrations of a human monoclonal antibody against the p40 subunit of IL-12/23 (IL-12/23 mAb) in subjects with moderate-to-severe psoriasis...
  42. ncbi request reprint Etanercept therapy in patients with autoimmunity and hepatitis C
    M Khanna
    Department of Medicine and Clinical Research Center, UMDNJ Robert Wood Johnson Medical School, 51 French Street, New Brunswick, NJ 08901 0019, USA
    J Dermatolog Treat 14:229-32. 2003
    ..Additionally, etanercept may actually be of benefit, when used in combination with standard treatments, for hepatitis C...
  43. pmc Treating psoriatic arthritis: how effective are TNF antagonists?
    Alice B Gottlieb
    Clinical Research Center UMDNJ RWJ Medical School, New Brunswick, NJ, USA
    Arthritis Res Ther 6:S31-5. 2004
    ..Clinical trials with these two agents in patients with PsA have shown significant improvement in the rheumatologic and cutaneous manifestations of the disease...
  44. ncbi request reprint Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis
    Frank C Victor
    Clinical Research Center, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903, USA
    Clin Dermatol 21:392-7. 2003
    ..The role of TNF-alpha in the pathogenesis of psoriasis is reviewed, along with clinical trials demonstrating the efficacy of new anti-TNF-alpha immunobiologics in the treatment of psoriasis and psoriatic arthritis...
  45. ncbi request reprint Psoriasis and psoriatic arthritis: clinical features and disease mechanisms
    Wendy A Myers
    Psoriasis Center of Excellence, UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA
    Clin Dermatol 24:438-47. 2006
    ....
  46. ncbi request reprint New-onset, debilitating arthritis in psoriasis patients receiving efalizumab
    Wendy A Myers
    Department of Medicine, Division of Clinical Pharmacology, UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA
    J Dermatolog Treat 17:353-4. 2006
    ..It can be speculated that a possible mechanism for efalizumab-induced psoriatic arthritis is related to the blockade of regulatory T cells from joint tissue...
  47. ncbi request reprint Induction of lesional and circulating leukocyte apoptosis by infliximab in a patient with moderate to severe psoriasis
    Rama Malaviya
    University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, NJ 08903 0019, USA
    J Drugs Dermatol 5:890-3. 2006
    ..In this report we demonstrate induction of plaque (T cells, dendritic cells) and peripheral blood (T cells, monocytes) leukocyte apoptosis following a single infliximab infusion in a psoriasis patient...
  48. ncbi request reprint Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody
    Alice B Gottlieb
    University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
    J Am Acad Dermatol 47:692-700. 2002
    ..The serum half-life of IDEC-114 was approximately 13 days. A single dose of IDEC-114 appears to be safe and well tolerated and has promising clinical activity in psoriasis...
  49. ncbi request reprint Psoriasis: emerging therapeutic strategies
    Alice B Gottlieb
    Clinical Research Center, UMDNJ Robert Wood Johnson Medical School, 51 French Street, New Brunswick, New Jersey 08901 0019, USA
    Nat Rev Drug Discov 4:19-34. 2005
    ....
  50. ncbi request reprint An open-label study to evaluate the transition of patients with chronic plaque psoriasis from cyclosporine to alefacept
    Melissa A Magliocco
    Division of Clinical Pharmacology, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
    J Drugs Dermatol 6:424-7. 2007
    ..Quality of life improved or was maintained in all patients. Adverse events and reductions in CD4+ T cell counts were consistent with those seen during alefacept monotherapy...
  51. ncbi request reprint Infliximab for psoriasis
    Alice B Gottlieb
    Clinical Research Center, UMDNJ Robert Wood Johnson Medical School, 51 French Street, New Brunswick, NJ 08901 0019, USA
    J Am Acad Dermatol 49:S112-7. 2003
    ..These results provide a convincing argument for the role of TNF-alpha in the pathogenesis of psoriasis and for the clinical development of infliximab for the treatment of psoriasis...
  52. ncbi request reprint TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques
    Alice B Gottlieb
    Clinical Research Center, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
    J Immunol 175:2721-9. 2005
    ..This results in reversal of the epidermal hyperplasia and cutaneous inflammation characteristic of psoriatic plaques...
  53. ncbi request reprint Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial
    Alice B Gottlieb
    University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey 08901 0019, USA
    J Am Acad Dermatol 54:S154-63. 2006
    ..Efalizumab is a T cell-targeted therapy for psoriasis...
  54. ncbi request reprint Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database
    Alice B Gottlieb
    Clinical Research Center, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, NJ 08901 0019, USA
    J Am Acad Dermatol 54:S92-100. 2006
    ..Etanercept, a tumor necrosis factor antagonist, is an approved treatment in the United States and Europe for plaque psoriasis...
  55. ncbi request reprint Etanercept for the treatment of psoriasis and psoriatic arthritis
    Alice B Gottlieb
    Clinical Research Center, UMDNJ Robert Wood Johnson Medical School, New Brunswick, New Jersey 08901 0019, USA
    Dermatol Ther 17:401-8. 2004
    ..Long term safety data of etanercept in the over 231,000 adults and children with rheumatoid arthritis who have been treated worldwide will be briefly summarized...
  56. ncbi request reprint Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis
    Alice B Gottlieb
    Clinical Research Center, UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ 08901 0019, USA
    J Drugs Dermatol 3:614-24. 2004
    ..The majority of patients experienced sustained efficacy with no increase in toxicity. This study is planned to continue; patients will receive up to 36 months of continuous efalizumab...
  57. ncbi request reprint Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept
    Paul F Lizzul
    Clinical Research Center, UMDNJ Robert Wood Johnson Medical School, New Brunswick, New Jersey 08901 0019, USA
    J Invest Dermatol 124:1275-83. 2005
    ..These data suggest that activation of NF-kappaB plays a significant role in the pathogenesis of psoriasis and that a potential mechanism of action for TNF-targeting agents is downregulation of NF-kappaB transcriptional activity...
  58. ncbi request reprint Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents
    Alexa Boer Kimball
    Clinical Unit for Research Trials in Skin, Massachusetts General and Brigham and Women s Hospitals, Harvard Medical School, Boston, Massachusetts
    J Am Acad Dermatol 59:448-54, 454.e1. 2008
    ..Clobetasol propionate 0.05% emulsion foam was recently developed for use on multiple body sites...
  59. ncbi request reprint Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis
    Deborah L Mortensen
    Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080 4990, USA
    J Clin Pharmacol 45:286-98. 2005
    ..Maximal pharmacodynamic effects were sustained at both dose levels through the course of treatment and were commensurate with improvements in psoriasis...
  60. ncbi request reprint Connections between psoriasis and Crohn's disease
    David James Najarian
    University of Virginia School of Medicine, USA
    J Am Acad Dermatol 48:805-21; quiz 822-4. 2003
    ....
  61. ncbi request reprint Developments in systemic immunomodulatory therapy for psoriasis
    Emily M Berger
    Department of Dermatology, Tufts New England Medical Center, Tufts University School of Medicine, Tufts NEMC Box 114, 750 Washington Street, Boston, MA 02111, United States
    Curr Opin Pharmacol 7:434-44. 2007
    ..Tumor necrosis factor-blockers have controversial associations with certain cancers and infections. Biologics require clinical monitoring and have specific contraindications. Scientists are exploring several new therapeutic targets...
  62. ncbi request reprint An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis
    Eiko Toichi
    Department of Dermatology, Case Western Reserve University and University Hospitals of Cleveland, 2109 Adelbert Road, Cleveland, OH 44106, USA
    J Immunol 177:4917-26. 2006
    ....
  63. ncbi request reprint Tumor necrosis factor blockade: mechanism of action
    Alice B Gottlieb
    Department of Dermatology, Tufts New England Medical Center, Boston, Massachusetts 02111, USA
    J Investig Dermatol Symp Proc 12:1-4. 2007
    ....
  64. ncbi request reprint Treatment of palmoplantar psoriasis with intramuscular alefacept
    Wendy Myers
    Clinical Research Center, University of Medicine and Dentistry New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey 08901 0019, USA
    J Am Acad Dermatol 53:S127-9. 2005
    ..This report describes the use of alefacept in 2 patients with extensive and recalcitrant palmoplantar psoriasis who achieved significant improvements on alefacept therapy...
  65. ncbi request reprint Common clinical features and disease mechanisms of psoriasis and psoriatic arthritis
    Wendy Myers
    Clinical Research Center, UMDNJ Robert Wood Johnson Medical, School, 51 French Street, New Brunswick, NJ 08901, USA
    Curr Rheumatol Rep 6:306-13. 2004
    ..New immunomodulating therapies, which are being developed as our understanding of the involvement of innate and adaptive immunity advances, will provide patients with safer, more effective, long-term, management options...
  66. ncbi request reprint Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis--a multicenter, 3-week, open-label study
    Doris Staab
    Department for Pediatric Pneumology and Immunology, Charite Campus Virchow, Berlin, Germany
    Pediatr Dermatol 22:465-71. 2005
    ..A rapid onset of therapeutic effect was observed within the first four days of treatment. Pimecrolimus cream 1% is well tolerated in infants 3 to 23 months of age treated for 3 weeks, and results in minimal systemic exposure...
  67. ncbi request reprint Climatotherapy at the Dead Sea is a remittive therapy for psoriasis: combined effects on epidermal and immunologic activation
    Emmilia Hodak
    Department of Dermatology, Rabin Medical Center, Petah Tiqva, Israel
    J Am Acad Dermatol 49:451-7. 2003
    ..The beneficial effect of climatotherapy at the Dead Sea (CDS) for psoriasis has been established clinically but there is a striking lack of studies assessing its in vivo effect at the molecular and cellular levels...
  68. ncbi request reprint TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis
    Frank C Victor
    UMDNJ RWJMS Clinical Research Center, 51 French Street, P O Box 19, Acute Care Bldg 3rd Floor, New Brunswick, New Jersey 08901 0019, USA
    J Drugs Dermatol 1:264-75. 2002
    ..g. etanercept, infliximab) and apoptosis-inducing treatments that result in clinical improvement of the disease...
  69. ncbi request reprint The role of apoptosis in human epidermal keratinocytes
    Michelle Emily Weisfelner
    UMDNJ Robert Wood Johnson Medical School, 51 French Street, New Brunswick, NJ 08903, USA
    J Drugs Dermatol 2:385-91. 2003
    ....
  70. ncbi request reprint Pediatric psoriasis and psoriatic arthritis
    Debra Lewkowicz
    Clinical Research Center, UMDNJ Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903, USA
    Dermatol Ther 17:364-75. 2004
    ..This review attempts to define and consolidate the current state of knowledge with regards to this disease spectrum. The need for further clinical trials to investigate treatment options in the pediatric population is also discussed...